B2Broker: B2BinPay Joins Forces with Ledger to Offer Customized Limited Edition Hardware Wallets
19.7.2023 20:00:00 EEST | Business Wire | Press release
The collaboration between B2BinPay and Ledger, two leading companies in their industries, marks a significant achievement. Through this innovative partnership, customers can now access an exclusive offering: a branded Ledger Nano X hardware wallet.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230719252053/en/
B2BinPay Joins Forces with Ledger to Offer Customized Limited Edition Hardware Wallets (Graphic: Business Wire)
This limited edition wallet showcases a distinctive crypto-processing design and prominently displays the B2BinPay logo. The joint effort of these two companies combines their expertise to deliver an outstanding product for customers.
Two types of clients can access these exclusive ledgers:
1. New merchants and enterprise clients;
2. Existing loyal customers who have been supporting B2BinPay.
These branded ledgers serve as a disclosure of appreciation for their ongoing support.
To offer customers a smooth experience, B2BinPay will supply personalized promo codes for acquiring their hardware wallets. These distinct codes can be entered on Ledger's official website on the specified collaboration page, allowing individuals to secure their unique devices effortlessly.
Please note that only 1000 units of these branded wallets are available. This limited quantity underscores these devices' exclusivity and exceptional worth, making them highly coveted by cryptocurrency enthusiasts and collectors.
Advantages of Ledger
Ledger's reputable multicurrency devices have gained the trust of individuals seeking a secure way to store their cryptocurrency private keys offline. These devices provide unbeatable protection against hackers while offering simplicity in managing assets and ensuring transaction transparency.
The partnership between B2BinPay and Ledger allows clients to access the industry's leading solutions for crypto storage. With these reliable hardware wallets, clients can confidently diversify their portfolios and efficiently manage their assets while maintaining the highest level of security.
Through the collaboration of B2BinPay and Ledger, clients are guaranteed access to top-tier storage solutions. This empowers them to navigate the cryptocurrency world confidently and gives them enhanced control over their digital assets, providing peace of mind.
Advantages of B2BinPay
As an all-in-one solution for secure cryptocurrency transactions, B2BinPay empowers businesses to send, receive, convert, and accept crypto assets efficiently. With support for major cryptocurrencies, clients can easily consolidate their digital assets into their preferred fiat, coin, or stablecoin format.
The collaboration with Ledger strengthens its commitment to delivering reliable and efficient solutions for managing crypto assets. This partnership inspires confidence in their ability to meet the evolving needs of their valued clients while staying at the forefront of advancements in the FinTech industry.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230719252053/en/
Contact information
+44 2080 688 636
pr@b2broker.net
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom